Company intelligence / Profile preview

Hemex Health

Portland, Oregon, United Stateshemexhealth.com ↗

Ownership: Private
Employees: ~33
Development stage: Other

Overview

Hemex Health’s Gazelle platform has demonstrated rapid and accurate point-of-care diagnosis for hemoglobin disorders such as sickle cell disease and beta thalassemia. The malaria diagnostic has regulatory approval in several countries. The COVID‑19 FIA test developed with Mylab Discovery Solutions showed 99.4% accuracy compared to PCR and was under review for Emergency Use Authorization by the US FDA as of mid‑2022. Clinical results support use in low-resource settings with minimal training required.

Therapeutic areas: HematologyInfectious Diseases
Modalities: Device
Industry: Protein Biomarker Diagnostics

Partnerships

Case Western Reserve UniversityNovartis BiomeMylab Discovery SolutionsIndia Health FundeHealth AfricaCDC USAID /NIRTH /NIMR /IFAIN /FIND

Beyond the preview

Go deeper on Hemex Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemex Health.

Explore the full profile